|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 依前列醇长期治疗原发性肺动脉高压的临床资料分析显示文摘目的 观察依前列醇长期治疗原发性肺动脉高压 (PPH)的疗效。方法 临床诊断为PPH且心功能为Ⅲ~Ⅳ级的慢性充血性心力衰竭患者 69例 ,均接受依前列醇长期静脉连续注入治疗(起始剂量在 2~ 62ng·kg- 1 ·min- 1 范围内。在长期治疗中 ,药物剂量应根据患者的反应进行调整 ,剂量通常随治疗时间每 2个月增加 1次 ,每次增加 1~ 2ng·kg- 1 ·min- 1 )并观察其疗效。用右心导管法和超声心动图检查法对所有患者测量三尖瓣跨瓣压 (ΔP)和心输出量 (CO)。随访期间每 4个月用超声心动图检查法复查上述指标 1次。结果 PPH患者长期用依前列醇治疗后 ,ΔP由 (84 1± 2 4 1 )mmHg (1mmHg=0 1 33kPa)降至 (62 7± 1 8 2 )mmHg(P <0 0 1 ) ,CO由 (4 0 0± 1 2 2 )L/min升至 (4 70± 1 2 7)L/min(P <0 0 2 ) ,ΔP/CO由 2 2 8± 9 4降至 1 4 9± 6 5(P <0 0 1 )。结论 长期静脉连续注入依前列醇治疗PPH ,可使患者右室压力逐渐下降 ,CO增加 。 | 曹铁生 袁丽君 段云友 王作军 庄磊 Shelley M Shapiro Bruce H Brundage | 2003 | 中华内科杂志2003，42，2： | 16 |
| 2 | 糖尿病患者服用β受体阻滞剂的心血管事件风险显示文摘β受体阻滞剂可能有助于获得强化血糖控制的最大效果,但也存在发生严重低血糖的潜在风险。该研究旨在评估糖尿病患者服用β受体阻滞剂是否有效及其应用是否与严重低血糖有关。 | Tsujimoto T Sugiyama T Shapiro MF Noda M Kajio H 赵狄 练桂丽 | 2017 | 中华高血压杂志2017，25，6： | 6 |
| 3 | Embedded image coding using zerotrees of wavelet coefficients显示文摘 | Shapiro J M | | 0，，： | 5 |
| 4 | CTGF, intestinal stellate cells and carcinoid fi brogenesis显示文摘AIM: To investigate the role of small intestinal carcinoid tumor-derived fibrotic mediators, TGFβ1 and CTGF, in the mediation of fi brosis via activation of an 'intestinal' stellate cell. METHODS: GI carcinoid tumors were collected for Q RT-PCR analysis of CTGF and TGFβ1. Markers of stellate cell desmoplasia were identified in peritoneal fibrosis by immunohistochemistry and stellate cells cultured from fresh resected fibrotic tissue. CTGF and TGFβ1 were evaluated using quantitative tissue array profi ling (AQUA analysis) in a GI carcinoid tissue microarray (TMA) with immunostaining and correlated with clinical and histologically documented fi brosis. Serum CTGF was analyzed using a sandwich ELISA assay. RESULTS: Message levels of both CTGF and TGFβ1 in SI carcinoid tumors were signifi cantly increased (> 2-fold, P < 0.05) versus normal mucosa and gastric (non-f ibrotic) carcinoids. Activated stellate cells and markers of stellate cell-mediated fi brosis (vimentin, desmin) were identifi ed in histological fibrosis. An intestinal stellate cell was immunocytochemically and biochemically characterized and its TGFβ1 (10-7M) initiated CTGF transcription response (> 3-fold, P < 0.05) demonstrated. In SI carcinoid tumor patients with documented fi brosis, TMA analysis demonstrated higher CTGF immunostaining (AQUA Score: 92 ± 8; P <0.05), as well as elevated TGFβ1 (90.6 ± 4.4, P < 0.05). Plasma CTGF (normal 12.5 ± 2.6 ng/mL) was increased in SI carcinoid tumor patients (31 ± 10 ng/mL, P < 0.05) compared to non-fi brotic GI carcinoids (< 15 ng/mL).CONCLUSION: SI carcinoid tumor fibrosis is a CTGF/ TGFβ1-mediated stellate cell-driven fibrotic response. The delineation of the biology of fibrosis will facilitate diagnosis and enable development of agents to obviate its local and systemic complications. | M Kidd IM Modlin MD Shapiro RL Camp SM Mane W Usinger JR Murren | 2007 | World Journal of Gastroenterology2007，13，39： | 5 |
| 5 | Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab显示文摘AIM:To investigate the safety and efficacy of adding bevacizumab to first-line chemotherapy in metastatic colorectal cancer patients with peritoneal disease.METHODS:We compared rates of gastrointestinal perforation in patients with metastatic colorectal cancer and peritoneal disease receiving first-line chemotherapy with and without bevacizumab in three distinct cohorts:(1) the AGITG MAX trial(Phase Ⅲ randomised clinical trial comparing capecitabine vs capecitabine and bevacizumab vs capecitabine,bevacizumab and mitomycin C);(2) the prospective Treatment of Recurrent and Advanced Colorectal Cancer(TRACC) registry(any first-line regimen ± bevacizumab);and(3) two cancer centres in New South Wales,Australia [Macarthur Cancer Therapy Centre and Liverpool Cancer Therapy Centre(NSWCC) from January 2005 to Decenber 2012,(any first-line regimen ± bevacizumab).For the AGITG MAX trial capecitabine was compared to the other two arms(capecitabine/bevacizumab and capecitabine/bevacizumab/mitomycin C).In the AGITG MAX trial and the TRACC registry rates of gastrointestinal perforation were also collected in patients who did not have peritoneal metastases.Secondary endpoints included progression-free survival,chemotherapy duration,and overall survival.Time-toevent outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test.RESULTS:Eighty-four MAX,179 TRACC and 69 NSWCC patients had peritoneal disease.There were no gastrointestinal perforations recorded in either the MAX subgroup or the NSWCC cohorts.Of the patients without peritoneal disease in the MAX trial,4/300(1.3%) in the bevacizumab arms had gastrointestinal perforations compared to 1/123(0.8%) in the capecitabine alone arm.In the TRACC registry 3/126(2.4%) patients who had received bevacizumab had a gastrointestinal perforation compared to 1/53(1.9%) in the chemotherapy alone arm.In a further analysis of patients without peritoneal metastases in the TRACC registry,the rate of gastrointestinal perforations was 9/369(2.4%) in the chemotherapy/bevacizumab group and 5/177(2.8%) in the chemotherapy alone group.The addition of bevacizumab to chemotherapy was associated with improved progression-free survival in all three cohorts:MAX 6.9 m vs 4.9 m,HR = 0.64(95%CI:0.42-1.02);P = 0.063;TRACC 9.1 m vs 5.5 m,HR = 0.61(95%CI:0.37-0.86);P = 0.009;NSWCC 8.7 m vs 6.8 m,HR = 0.75(95%CI:0.43-1.32);P = 0.32.Chemotherapy duration was similar across the groups.CONCLUSION:Patients with peritoneal disease do not appear to have an increased risk of gastrointestinal perforations when receiving first-line therapy with bevacizumab compared to systemic therapy alone. | Aflah Roohullah Hui-Li Wong Katrin M Sjoquist Peter Gibbs Kathryn Field Ben Tran Jeremy Shapiro Joe Mckendrick Desmond Yip Louise Nott Val Gebski Weng Ng Wei Chua Timothy Price Niall Tebbutt Lorraine Chantrill | 2015 | World Journal of Gastroenterology2015，21，17： | 3 |
| 6 | Embedded image coding using zerotree of wavelet coefficients显示文摘 | Shapiro J M | | 0，，： | 2 |
| 7 | Embedding image coding using zerotrees of wavelet coefficients 显示文摘 | SHAPIRO J M | 1993 | IEEE Trans on Signal Processing1993，41，12： | 2 |
| 8 | Embedded Image Coding Using Zerotrees of Wavelet Coefficients 显示文摘 | Shapiro J M | 1993 | IEEE Transactions on Signal Processing1993，41，12： | 1 |
| 9 | Abdominal incision: decision or indecision? 显示文摘 | Cahalane M J Shapiro ME Silen W | 1989 | Lancet1989，8630，1： | 1 |
| 10 | Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in nonobese diabetic mice 显示文摘 | Shapiro A M Suarez-Pinzon W L Power R | 2002 | Diabetologia2002，45，2： | 1 |
| 11 | Systems Competition and Network Effects显示文摘 | KATZ M SHAPIRO C | 1994 | Journal of Economic Perspectives1994，8，2： | 1 |
| 12 | On Hurwitz numbers and Hodge integrals显示文摘 | Ekedahl T Lando S Shapiro M | 1999 | C R Acad Sci Paris Sér Math1999，328，： | 1 |
| 13 | Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice显示文摘 | Steven D Shapiro Nir M | 2003 | Am J Pathol2003，163，： | 1 |
| 14 | Free DNA in the serum of cancer patients and the effect of therapy显示文摘 | Leon S A Shapiro B Sklaroff D M | 1977 | Cancer Res1977，37，： | 1 |
| 15 | Free DNA in the serum of cancer patients and the effect of therapy显示文摘 | LEON S A SHAPIRO B SKLAROFF D M | 1997 | Cancer Res1997，37，3： | 1 |
| 16 | Embedded image coding using zerotrees of wavelet coefficients 显示文摘 | Shapiro J M | 1993 | IEEE Transactions on Signal Processing1993，41，12： | 1 |
| 17 | Universal vectors for operators on spaces of holomorphic functions显示文摘 | Gethner R M Shapiro J H | 1987 | Proc Amer Math Soc1987，100，2： | 1 |
| 18 | Feature-based correspondence: an eigenvector approach 显示文摘 | Shapiro L S Brady J M | 1992 | Image and Vision Computing1992，10，5： | 1 |
| 19 | Embedded Image Coding Using Zero Trees of Wavelet Coefficients显示文摘 | Shapiro J M | 1993 | IEEE Trans on Signal Processing1993，41，12： | 1 |
| 20 | A Multiscale Random Field Model for Bayesian Image Segmentation显示文摘 | C BOUMAN M SHAPIRO | 1994 | IEEE Transactions on Image Processing1994，3，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员